Javelin Pharmaceuticals, Inc. has signed a commercial supply agreement with Precision Pharma Services. Under the agreement, Precision will manufacture vials of Javelin’s injectable Dyloject product for use in European markets, pending regulatory approval. The agreement has a two-year, renewable term and includes minimum purchase and production requirements. “This agreement is an important step forward in growing Javelin’s manufacturing infrastructure in anticipation of ini...